04
Aug

Biotech startup Enumeral Biomedical has pulled off a deal that gives it $21.5 million in financing and access to public markets, paving the way for early-stage work on some cancer immunotherapies.

…read more

Source: Enumeral banks $21.5M for immuno-oncology R&D

    

0 No comments